advertisement

Colchicine Linked to Lower Mortality in Diabetes and Gout Cohort

Illustrated gout affected joint tissue beside a tablet representing colchicine use in patients with type 2 diabetes

11/16/2026

Key Takeaways

  • In a Korean cohort with type 2 diabetes and gout but no prior coronary artery disease, colchicine use was associated with lower all-cause mortality: 8% versus 11% among nonusers.
  • The composite of death, nonfatal myocardial infarction, and nonfatal stroke occurred in 13% of users versus 15% of nonusers; deaths drove the difference.
  • Neither nonfatal myocardial infarction nor nonfatal stroke differed significantly by colchicine use.
  • The lower-mortality association persisted but attenuated in a landmark analysis.
For people with type 2 diabetes prescribed colchicine for gout, it remains unclear whether mortality and individual cardiovascular events track together. Among those without prior coronary artery disease, a composite that includes death and nonfatal events may obscure differences between its components. Investigators compared colchicine recipients with nonrecipients and assessed those outcomes separately.

Shin and colleagues assembled a retrospective Korean National Health Insurance Service (NHIS) cohort from claims for adults newly diagnosed with type 2 diabetes during 2015–2019, identified through a diabetes diagnosis and antidiabetic prescription. Gout required a diagnosis with repeated outpatient encounters or a hospitalization; its diagnosis set the index date. Eligible patients had gout-related medication prescriptions and no prior coronary artery disease, although prior stroke or peripheral artery disease did not exclude them. Investigators formed 17,337 propensity-matched pairs based on demographics, comorbidities, and medications. Exposure meant at least one colchicine prescription after gout diagnosis versus none during follow-up, which began at the gout diagnosis date in both groups. The composite included all-cause death, nonfatal myocardial infarction, and nonfatal stroke. Investigators also performed outcome-specific 365-day landmark analyses; follow-up ended by December 31, 2023.

Colchicine use was associated with lower all-cause mortality, with a hazard ratio (HR) of 0.58 and a 95% confidence interval (CI) of 0.53–0.62. The mortality-driven composite also favored users (HR 0.71). Neither nonfatal myocardial infarction nor nonfatal stroke differed significantly between groups in the primary matched analysis.

In the landmark analysis, the mortality association persisted (HR 0.67; 95% CI 0.62–0.73), although it and the composite association were attenuated. Myocardial infarction and stroke again did not differ significantly. Cardiovascular death did not differ significantly; lower associations for cancer- and infection-related deaths were exploratory. An age- and sex-adjusted stroke association was not reproduced in the landmark analysis.

Starting follow-up at gout diagnosis while classifying exposure by a later prescription creates an immortal-time concern: future users had to remain alive long enough to receive colchicine. The landmark analysis addressed that timing issue but did not remove uncertainty from the observational comparison. Age remained imbalanced after matching, and healthy-user differences or gout severity could have influenced prescribing and outcomes. Claims lacked hemoglobin A1c (HbA1c), serum uric acid, and precise diabetes duration; one prescription also encompassed heterogeneous exposure. Because prior stroke or peripheral artery disease was allowed, excluding coronary artery disease did not establish that every participant was free of atherosclerotic disease. The findings reflect a Korean population and prescribing context rather than demonstrated applicability elsewhere.

The researchers concluded that colchicine prescriptions for gout remained associated with lower all-cause mortality after the landmark analysis, whereas individual myocardial infarction and stroke outcomes did not differ significantly. They cautioned that these observational findings do not establish causation or cardiovascular primary-prevention efficacy and called for randomized confirmation.

Clinician Questions

Do the Korean colchicine findings in diabetes and gout apply to patients without gout?

Shin and colleagues studied Korean patients with both type 2 diabetes and gout who received gout-related medication, not patients with diabetes but no gout. In the Korean prescribing context they describe, national insurance reimburses colchicine for gout-related indications; non-gout prescribing is subject to claims denial and physician penalties. The findings do not establish applicability to patients without gout.

How were myocardial infarction, stroke, and death identified among Korean patients with diabetes and gout?

Among Korean patients with type 2 diabetes and gout compared by colchicine prescription status, nonfatal myocardial infarction and nonfatal stroke were identified through hospitalization International Classification of Diseases, Tenth Revision (ICD-10) codes I21 and I63/I64, respectively. All-cause death was ascertained from the National Death Registry.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

NEW FEATURES:

Register

We're glad to see you're enjoying Global Cardiology Academy…
but how about a more personalized experience?

Register for free